{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:47:14Z","timestamp":1782931634847,"version":"3.54.5"},"reference-count":32,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-03774"],"award-info":[{"award-number":["2021-03774"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["20210928"],"award-info":[{"award-number":["20210928"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005753","name":"Royal Physiographic Society of Lund","doi-asserted-by":"publisher","award":["2021-03774"],"award-info":[{"award-number":["2021-03774"]}],"id":[{"id":"10.13039\/501100005753","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005753","name":"Royal Physiographic Society of Lund","doi-asserted-by":"publisher","award":["20210928"],"award-info":[{"award-number":["20210928"]}],"id":[{"id":"10.13039\/501100005753","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JFB"],"abstract":"<jats:p>Osteosarcoma treatment comprises pre-surgical chemotherapy followed by radical surgery and further chemotherapy cycles, but the prognosis has been far from satisfactory. No new drugs or treatment modalities have been developed for clinical use in the last four decades. We describe a nano-hydroxyapatite (HA)-based local drug delivery platform for the delivery of doxorubicin (DOX), a cornerstone drug in osteosarcoma treatment. The efficacy of the developed drug delivery system was evaluated in an orthotopic human osteosarcoma xenograft in the proximal tibia of mice. After tumor development, the tumor was surgically resected and the void filled with the following: (1) No treatment (G1); (2) nHA only (G2); (3) DOX-loaded nHA (G3). In-vivo tumor response was assessed by evaluating the tumor-induced osteolysis at 2 weeks using micro-CT followed by in-vivo PET-CT at 3 weeks and ex-vivo micro-CT and histology. Micro-CT imaging revealed complete destruction of the tibial metaphysis in groups G1 and G2, while the metaphysis was protected from osteolysis in G3. PET-CT imaging using 18F-FDG revealed high metabolic activity in the tumors in G1 and G2, which was significantly reduced in G3. Using histology, we were able to verify that local DOX delivery reduced the bone destruction and the tumor burden compared with G1 and G2. No off-target toxicity in the vital organs could be observed in any of the treatment groups histologically. This study describes a novel local drug adjuvant delivery approach that could potentially improve the prognosis for patients responding poorly to the current osteosarcoma treatment.<\/jats:p>","DOI":"10.3390\/jfb15080232","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T01:38:45Z","timestamp":1724117925000},"page":"232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Surgery Combined with Local Implantation of Doxorubicin-Functionalized Hydroxyapatite Halts Tumor Growth and Prevents Bone Destruction in an Aggressive Osteosarcoma"],"prefix":"10.3390","volume":"15","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, 221 00 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tova","family":"Corbascio","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, 221 00 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, 221 00 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Engellau","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, 221 00 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lidgren","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, 221 00 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"T\u00e4gil","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, 221 00 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8767-892X","authenticated-orcid":false,"given":"Deepak Bushan","family":"Raina","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Lund, Orthopedics, The Faculty of Medicine, Lund University, 221 00 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrclinonc.2014.153","article-title":"Clinical cancer research: The past, present and the future","volume":"11","author":"DeVita","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra2103423","article-title":"New Horizons in the Treatment of Osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1158\/0008-5472.CAN-09-1750","article-title":"Cancer prevention: From 1727 to milestones of the past 100 years","volume":"69","author":"Lippman","year":"2009","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"114075","DOI":"10.1016\/j.addr.2021.114075","article-title":"Responsive nanomedicines enhanced by or enhancing physical modalities to treat solid cancer tumors: Preclinical and clinical evidence of safety and efficacy","volume":"181","author":"Papaioannou","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s11999-012-2590-2","article-title":"Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma","volume":"471","author":"Wong","year":"2013","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F","article-title":"Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival","volume":"75","author":"Saeter","year":"1995","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols","volume":"20","author":"Bielack","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-04843-7_1","article-title":"Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma","volume":"804","author":"Jaffe","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e15582","DOI":"10.1097\/MD.0000000000015582","article-title":"Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation","volume":"98","author":"Yu","year":"2019","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: Current Treatment and a Collaborative Pathway to Success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","article-title":"Survival and prognosis with osteosarcoma: Outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort","volume":"109","author":"Smeland","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: Myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jconrel.2014.04.048","article-title":"Controlled release for local delivery of drugs: Barriers and models","volume":"190","author":"Weiser","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13046-023-02731-z","article-title":"Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma","volume":"42","author":"Cascini","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11914-023-00803-9","article-title":"Advances in Osteosarcoma","volume":"21","author":"Heymann","year":"2023","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nmat2309","article-title":"Drug delivery: The heart of the matter","volume":"7","author":"Putnam","year":"2008","journal-title":"Nat. Mater."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.actbio.2021.07.016","article-title":"Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma","volume":"131","author":"Liu","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Liu, Y., Nadeem, A., Sebastian, S., Olsson, M.A., Wai, S.N., Styring, E., Engellau, J., Isaksson, H., T\u00e4gil, M., and Lidgren, L. (2022). Bone mineral: A trojan horse for bone cancers. Efficient mitochondria targeted delivery and tumor eradication with nano hydroxyapatite containing doxorubicin. Mater. Today Bio, 14.","DOI":"10.1016\/j.mtbio.2022.100227"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/bjc.2013.549","article-title":"Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes","volume":"109","author":"Lauvrak","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16649","DOI":"10.1073\/pnas.0607705103","article-title":"A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas","volume":"103","author":"Lee","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2174\/1567201818666210609161301","article-title":"Targeted Drug Delivery: Trends and Perspectives","volume":"18","author":"Ashique","year":"2021","journal-title":"Curr. Drug Deliv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pilavaki, P., Gahanbani Ardakani, A., Gikas, P., and Constantinidou, A. (2023). Osteosarcoma: Current Concepts and Evolutions in Management Principles. J. Clin. Med., 12.","DOI":"10.3390\/jcm12082785"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hum, N.R., Martin, K.A., Malfatti, M.A., Haack, K., Buchholz, B.A., and Loots, G.G. (2018). Tracking Tumor Colonization in Xenograft Mouse Models Using Accelerator Mass Spectrometry. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-33368-0"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Liu, Z., Wang, Y., Kabraji, S., Xie, S., Pan, P., Liu, Z., Ni, J., and Zhao, J.J. (2019). Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method. Sci. Rep., 9.","DOI":"10.1038\/s41598-018-36874-3"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Liu, G., Yang, L., Chen, G., Xu, F., Yang, F., Yu, H., Li, L., Dong, X., Han, J., and Cao, C. (2021). A Review on Drug Delivery System for Tumor Therapy. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.735446"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.amjsurg.2011.06.027","article-title":"Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo","volume":"202","author":"Cohen","year":"2011","journal-title":"Am. J. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40001-021-00593-9","article-title":"Strategies for large bone defect reconstruction after trauma, infections or tumour excision: A comprehensive review of the literature","volume":"26","author":"Migliorini","year":"2021","journal-title":"Eur. J. Med. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.biomaterials.2018.07.017","article-title":"Bone regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells current stage and future perspectives","volume":"180","author":"Bolander","year":"2018","journal-title":"Biomaterials"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: The good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41565-021-01017-9","article-title":"The ancillary effects of nanoparticles and their implications for nanomedicine","volume":"16","author":"Stater","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, Y., Sebastian, S., Huang, J., Corbascio, T., Engellau, J., Lidgren, L., T\u00e4gil, M., and Raina, D.B. (2022). Longitudinal in vivo biodistribution of nano and micro sized hydroxyapatite particles implanted in a bone defect. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.1076320"}],"container-title":["Journal of Functional Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4983\/15\/8\/232\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:39:14Z","timestamp":1760110754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4983\/15\/8\/232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jfb15080232"],"URL":"https:\/\/doi.org\/10.3390\/jfb15080232","relation":{},"ISSN":["2079-4983"],"issn-type":[{"value":"2079-4983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}